A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novartis' Rhapsido shows promise in Phase 2 food allergy data
Novartis' Rhapsido shows promise in Phase 2 food allergy data
Novartis, Takeda to enter next Medicare drug price negotiations
Novartis, Takeda to enter next Medicare drug price negotiations
CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives
CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives
Novartis closes Avidity deal as rare heart disease spinout launches
Novartis closes Avidity deal as rare heart disease spinout launches
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Novartis to divest India unit to private equity-led consortium for $159M
Novartis to divest India unit to private equity-led consortium for $159M
Updated: Novartis signs macrocyclic deal with Unnatural Products
Updated: Novartis signs macrocyclic deal with Unnatural Products
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Novartis says generics to erode $4B from 2026 sales
Novartis says generics to erode $4B from 2026 sales
Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
Novartis to build fourth US radiotherapy factory in Florida
Novartis to build fourth US radiotherapy factory in Florida
Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A
Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A
Novartis to partner with AI-focused Relation on atopic diseases
Novartis to partner with AI-focused Relation on atopic diseases
#ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?
#ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?
Novartis was the sole bidder in $12B deal to buy Avidity
It took 14 calls between chief executives, four months of negotiations and four hiked proposals for Novartis and Avidity Biosciences to come to their $12 billion agreem...
#ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 wins
Late-breaking abstracts from the annual American Society of Hematology meeting are early this year, coming right before Thanksgiving instead of the previously planned d...
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page